img

Global Biosimilars Insulin Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Biosimilars Insulin Market Research Report 2024

Biosimilars is a biological product designed to have similar active properties to the one that has been previously licensed and has no clinically significant differences in terms of safety and effectiveness. Biosimilars insulin is a type of biosimilars where it is indistinguishable to the reference insulin product and is already been approved by FDA or licensed. The producers of biosimilars use the similar manufacturing techniques as of the patented product but not likely identical to that used by the patent holder. Due to increasing insulin manufacturers from the developed and developing countries, the patents for insulin formulations had neared expiry or were ended. This created a necessity to seek approvals on biosimilar insulin for the not yet established companies in the highly regulated markets such as Europe and United States. In 2014, The European Commission (EC) first granted insulin treatment through the biosimilars pathway to Eli Lilly and Company and Boehringer Ingelheim GmbH. Lilly/Boehringer Ingelheim developed a biosimilar insulin called “Insulin glargine” and was the fourth diabetes product which was approved from Lilly-Boehringer Ingelheim Alliance in Europe. Basaglar is the first “biosimilar” insulin product to be approved and launched in U.S. which was developed by the alliance of Lilly/Boehringer Ingelheim.
According to Mr Accuracy reports’s new survey, global Biosimilars Insulin market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Biosimilars Insulin market research.
Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market. However, Insulin patent protection rights and strong retaliation from the branded manufactures has restricted the growth of insulin biosimilar development.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Biosimilars Insulin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Eli Lilly
Boehringer Ingelheim
Biocon/Mylan
Gan & Lee Pharmaceuticals
Tonghua Dongbao
United Laboratories
Sanofi
Segment by Type
Insulin Glargine
Insulin Aspart
Insulin Lispro
Other

Segment by Application


Type I Diabetes
Type II Diabetes

Consumption by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Biosimilars Insulin report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Biosimilars Insulin Market Overview
1.1 Product Overview and Scope of Biosimilars Insulin
1.2 Biosimilars Insulin Segment by Type
1.2.1 Global Biosimilars Insulin Market Value Comparison by Type (2024-2034)
1.2.2 Insulin Glargine
1.2.3 Insulin Aspart
1.2.4 Insulin Lispro
1.2.5 Other
1.3 Biosimilars Insulin Segment by Application
1.3.1 Global Biosimilars Insulin Market Value by Application: (2024-2034)
1.3.2 Type I Diabetes
1.3.3 Type II Diabetes
1.4 Global Biosimilars Insulin Market Size Estimates and Forecasts
1.4.1 Global Biosimilars Insulin Revenue 2018-2034
1.4.2 Global Biosimilars Insulin Sales 2018-2034
1.4.3 Global Biosimilars Insulin Market Average Price (2018-2034)
1.5 Assumptions and Limitations
2 Biosimilars Insulin Market Competition by Manufacturers
2.1 Global Biosimilars Insulin Sales Market Share by Manufacturers (2018-2023)
2.2 Global Biosimilars Insulin Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Biosimilars Insulin Average Price by Manufacturers (2018-2023)
2.4 Global Biosimilars Insulin Industry Ranking 2021 VS 2024 VS 2023
2.5 Global Key Manufacturers of Biosimilars Insulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilars Insulin, Product Type & Application
2.7 Biosimilars Insulin Market Competitive Situation and Trends
2.7.1 Biosimilars Insulin Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Biosimilars Insulin Players Market Share by Revenue
2.7.3 Global Biosimilars Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biosimilars Insulin Retrospective Market Scenario by Region
3.1 Global Biosimilars Insulin Market Size by Region: 2018 Versus 2024 Versus 2034
3.2 Global Biosimilars Insulin Global Biosimilars Insulin Sales by Region: 2018-2034
3.2.1 Global Biosimilars Insulin Sales by Region: 2018-2023
3.2.2 Global Biosimilars Insulin Sales by Region: 2024-2034
3.3 Global Biosimilars Insulin Global Biosimilars Insulin Revenue by Region: 2018-2034
3.3.1 Global Biosimilars Insulin Revenue by Region: 2018-2023
3.3.2 Global Biosimilars Insulin Revenue by Region: 2024-2034
3.4 North America Biosimilars Insulin Market Facts & Figures by Country
3.4.1 North America Biosimilars Insulin Market Size by Country: 2018 VS 2024 VS 2034
3.4.2 North America Biosimilars Insulin Sales by Country (2018-2034)
3.4.3 North America Biosimilars Insulin Revenue by Country (2018-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biosimilars Insulin Market Facts & Figures by Country
3.5.1 Europe Biosimilars Insulin Market Size by Country: 2018 VS 2024 VS 2034
3.5.2 Europe Biosimilars Insulin Sales by Country (2018-2034)
3.5.3 Europe Biosimilars Insulin Revenue by Country (2018-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilars Insulin Market Facts & Figures by Country
3.6.1 Asia Pacific Biosimilars Insulin Market Size by Country: 2018 VS 2024 VS 2034
3.6.2 Asia Pacific Biosimilars Insulin Sales by Country (2018-2034)
3.6.3 Asia Pacific Biosimilars Insulin Revenue by Country (2018-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biosimilars Insulin Market Facts & Figures by Country
3.7.1 Latin America Biosimilars Insulin Market Size by Country: 2018 VS 2024 VS 2034
3.7.2 Latin America Biosimilars Insulin Sales by Country (2018-2034)
3.7.3 Latin America Biosimilars Insulin Revenue by Country (2018-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Biosimilars Insulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilars Insulin Market Size by Country: 2018 VS 2024 VS 2034
3.8.2 Middle East and Africa Biosimilars Insulin Sales by Country (2018-2034)
3.8.3 Middle East and Africa Biosimilars Insulin Revenue by Country (2018-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biosimilars Insulin Sales by Type (2018-2034)
4.1.1 Global Biosimilars Insulin Sales by Type (2018-2023)
4.1.2 Global Biosimilars Insulin Sales by Type (2024-2034)
4.1.3 Global Biosimilars Insulin Sales Market Share by Type (2018-2034)
4.2 Global Biosimilars Insulin Revenue by Type (2018-2034)
4.2.1 Global Biosimilars Insulin Revenue by Type (2018-2023)
4.2.2 Global Biosimilars Insulin Revenue by Type (2024-2034)
4.2.3 Global Biosimilars Insulin Revenue Market Share by Type (2018-2034)
4.3 Global Biosimilars Insulin Price by Type (2018-2034)
5 Segment by Application
5.1 Global Biosimilars Insulin Sales by Application (2018-2034)
5.1.1 Global Biosimilars Insulin Sales by Application (2018-2023)
5.1.2 Global Biosimilars Insulin Sales by Application (2024-2034)
5.1.3 Global Biosimilars Insulin Sales Market Share by Application (2018-2034)
5.2 Global Biosimilars Insulin Revenue by Application (2018-2034)
5.2.1 Global Biosimilars Insulin Revenue by Application (2018-2023)
5.2.2 Global Biosimilars Insulin Revenue by Application (2024-2034)
5.2.3 Global Biosimilars Insulin Revenue Market Share by Application (2018-2034)
5.3 Global Biosimilars Insulin Price by Application (2018-2034)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Corporation Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Eli Lilly Biosimilars Insulin Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Boehringer Ingelheim
6.2.1 Boehringer Ingelheim Corporation Information
6.2.2 Boehringer Ingelheim Description and Business Overview
6.2.3 Boehringer Ingelheim Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Boehringer Ingelheim Biosimilars Insulin Product Portfolio
6.2.5 Boehringer Ingelheim Recent Developments/Updates
6.3 Biocon/Mylan
6.3.1 Biocon/Mylan Corporation Information
6.3.2 Biocon/Mylan Description and Business Overview
6.3.3 Biocon/Mylan Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Biocon/Mylan Biosimilars Insulin Product Portfolio
6.3.5 Biocon/Mylan Recent Developments/Updates
6.4 Gan & Lee Pharmaceuticals
6.4.1 Gan & Lee Pharmaceuticals Corporation Information
6.4.2 Gan & Lee Pharmaceuticals Description and Business Overview
6.4.3 Gan & Lee Pharmaceuticals Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Gan & Lee Pharmaceuticals Biosimilars Insulin Product Portfolio
6.4.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
6.5 Tonghua Dongbao
6.5.1 Tonghua Dongbao Corporation Information
6.5.2 Tonghua Dongbao Description and Business Overview
6.5.3 Tonghua Dongbao Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Tonghua Dongbao Biosimilars Insulin Product Portfolio
6.5.5 Tonghua Dongbao Recent Developments/Updates
6.6 United Laboratories
6.6.1 United Laboratories Corporation Information
6.6.2 United Laboratories Description and Business Overview
6.6.3 United Laboratories Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
6.6.4 United Laboratories Biosimilars Insulin Product Portfolio
6.6.5 United Laboratories Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Biosimilars Insulin Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Sanofi Biosimilars Insulin Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilars Insulin Industry Chain Analysis
7.2 Biosimilars Insulin Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilars Insulin Production Mode & Process
7.4 Biosimilars Insulin Sales and Marketing
7.4.1 Biosimilars Insulin Sales Channels
7.4.2 Biosimilars Insulin Distributors
7.5 Biosimilars Insulin Customers
8 Biosimilars Insulin Market Dynamics
8.1 Biosimilars Insulin Industry Trends
8.2 Biosimilars Insulin Market Drivers
8.3 Biosimilars Insulin Market Challenges
8.4 Biosimilars Insulin Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Biosimilars Insulin Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Biosimilars Insulin Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Biosimilars Insulin Market Competitive Situation by Manufacturers in 2024
Table 4. Global Biosimilars Insulin Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Biosimilars Insulin Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Biosimilars Insulin Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Biosimilars Insulin Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Biosimilars Insulin Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Biosimilars Insulin, Industry Ranking, 2021 VS 2024 VS 2023
Table 10. Global Key Manufacturers of Biosimilars Insulin, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Biosimilars Insulin, Product Type & Application
Table 12. Global Key Manufacturers of Biosimilars Insulin, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Biosimilars Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilars Insulin as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Biosimilars Insulin Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 17. Global Biosimilars Insulin Sales by Region (2018-2023) & (K Units)
Table 18. Global Biosimilars Insulin Sales Market Share by Region (2018-2023)
Table 19. Global Biosimilars Insulin Sales by Region (2024-2034) & (K Units)
Table 20. Global Biosimilars Insulin Sales Market Share by Region (2024-2034)
Table 21. Global Biosimilars Insulin Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Biosimilars Insulin Revenue Market Share by Region (2018-2023)
Table 23. Global Biosimilars Insulin Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Biosimilars Insulin Revenue Market Share by Region (2024-2034)
Table 25. North America Biosimilars Insulin Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 26. North America Biosimilars Insulin Sales by Country (2018-2023) & (K Units)
Table 27. North America Biosimilars Insulin Sales by Country (2024-2034) & (K Units)
Table 28. North America Biosimilars Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Biosimilars Insulin Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Biosimilars Insulin Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 31. Europe Biosimilars Insulin Sales by Country (2018-2023) & (K Units)
Table 32. Europe Biosimilars Insulin Sales by Country (2024-2034) & (K Units)
Table 33. Europe Biosimilars Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Biosimilars Insulin Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Biosimilars Insulin Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 36. Asia Pacific Biosimilars Insulin Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Biosimilars Insulin Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Biosimilars Insulin Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Biosimilars Insulin Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Biosimilars Insulin Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 41. Latin America Biosimilars Insulin Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Biosimilars Insulin Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Biosimilars Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Biosimilars Insulin Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Biosimilars Insulin Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 46. Middle East & Africa Biosimilars Insulin Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Biosimilars Insulin Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Biosimilars Insulin Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Biosimilars Insulin Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Biosimilars Insulin Sales (K Units) by Type (2018-2023)
Table 51. Global Biosimilars Insulin Sales (K Units) by Type (2024-2034)
Table 52. Global Biosimilars Insulin Sales Market Share by Type (2018-2023)
Table 53. Global Biosimilars Insulin Sales Market Share by Type (2024-2034)
Table 54. Global Biosimilars Insulin Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Biosimilars Insulin Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Biosimilars Insulin Revenue Market Share by Type (2018-2023)
Table 57. Global Biosimilars Insulin Revenue Market Share by Type (2024-2034)
Table 58. Global Biosimilars Insulin Price (USD/Unit) by Type (2018-2023)
Table 59. Global Biosimilars Insulin Price (USD/Unit) by Type (2024-2034)
Table 60. Global Biosimilars Insulin Sales (K Units) by Application (2018-2023)
Table 61. Global Biosimilars Insulin Sales (K Units) by Application (2024-2034)
Table 62. Global Biosimilars Insulin Sales Market Share by Application (2018-2023)
Table 63. Global Biosimilars Insulin Sales Market Share by Application (2024-2034)
Table 64. Global Biosimilars Insulin Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Biosimilars Insulin Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Biosimilars Insulin Revenue Market Share by Application (2018-2023)
Table 67. Global Biosimilars Insulin Revenue Market Share by Application (2024-2034)
Table 68. Global Biosimilars Insulin Price (USD/Unit) by Application (2018-2023)
Table 69. Global Biosimilars Insulin Price (USD/Unit) by Application (2024-2034)
Table 70. Eli Lilly Corporation Information
Table 71. Eli Lilly Description and Business Overview
Table 72. Eli Lilly Biosimilars Insulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 73. Eli Lilly Biosimilars Insulin Product
Table 74. Eli Lilly Recent Developments/Updates
Table 75. Boehringer Ingelheim Corporation Information
Table 76. Boehringer Ingelheim Description and Business Overview
Table 77. Boehringer Ingelheim Biosimilars Insulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 78. Boehringer Ingelheim Biosimilars Insulin Product
Table 79. Boehringer Ingelheim Recent Developments/Updates
Table 80. Biocon/Mylan Corporation Information
Table 81. Biocon/Mylan Description and Business Overview
Table 82. Biocon/Mylan Biosimilars Insulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 83. Biocon/Mylan Biosimilars Insulin Product
Table 84. Biocon/Mylan Recent Developments/Updates
Table 85. Gan & Lee Pharmaceuticals Corporation Information
Table 86. Gan & Lee Pharmaceuticals Description and Business Overview
Table 87. Gan & Lee Pharmaceuticals Biosimilars Insulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 88. Gan & Lee Pharmaceuticals Biosimilars Insulin Product
Table 89. Gan & Lee Pharmaceuticals Recent Developments/Updates
Table 90. Tonghua Dongbao Corporation Information
Table 91. Tonghua Dongbao Description and Business Overview
Table 92. Tonghua Dongbao Biosimilars Insulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 93. Tonghua Dongbao Biosimilars Insulin Product
Table 94. Tonghua Dongbao Recent Developments/Updates
Table 95. United Laboratories Corporation Information
Table 96. United Laboratories Description and Business Overview
Table 97. United Laboratories Biosimilars Insulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 98. United Laboratories Biosimilars Insulin Product
Table 99. United Laboratories Recent Developments/Updates
Table 100. Sanofi Corporation Information
Table 101. Sanofi Description and Business Overview
Table 102. Sanofi Biosimilars Insulin Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 103. Sanofi Biosimilars Insulin Product
Table 104. Sanofi Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Biosimilars Insulin Distributors List
Table 108. Biosimilars Insulin Customers List
Table 109. Biosimilars Insulin Market Trends
Table 110. Biosimilars Insulin Market Drivers
Table 111. Biosimilars Insulin Market Challenges
Table 112. Biosimilars Insulin Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Biosimilars Insulin
Figure 2. Global Biosimilars Insulin Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Biosimilars Insulin Market Share by Type in 2024 & 2034
Figure 4. Insulin Glargine Product Picture
Figure 5. Insulin Aspart Product Picture
Figure 6. Insulin Lispro Product Picture
Figure 7. Other Product Picture
Figure 8. Global Biosimilars Insulin Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 9. Global Biosimilars Insulin Market Share by Application in 2024 & 2034
Figure 10. Type I Diabetes
Figure 11. Type II Diabetes
Figure 12. Global Biosimilars Insulin Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Biosimilars Insulin Market Size (2018-2034) & (US$ Million)
Figure 14. Global Biosimilars Insulin Sales (2018-2034) & (K Units)
Figure 15. Global Biosimilars Insulin Average Price (USD/Unit) & (2018-2034)
Figure 16. Biosimilars Insulin Report Years Considered
Figure 17. Biosimilars Insulin Sales Share by Manufacturers in 2024
Figure 18. Global Biosimilars Insulin Revenue Share by Manufacturers in 2024
Figure 19. The Global 5 and 10 Largest Biosimilars Insulin Players: Market Share by Revenue in 2024
Figure 20. Biosimilars Insulin Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2024
Figure 21. Global Biosimilars Insulin Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Figure 22. North America Biosimilars Insulin Sales Market Share by Country (2018-2034)
Figure 23. North America Biosimilars Insulin Revenue Market Share by Country (2018-2034)
Figure 24. United States Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 25. Canada Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 26. Europe Biosimilars Insulin Sales Market Share by Country (2018-2034)
Figure 27. Europe Biosimilars Insulin Revenue Market Share by Country (2018-2034)
Figure 28. Germany Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 29. France Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 30. U.K. Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 31. Italy Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 32. Russia Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 33. Asia Pacific Biosimilars Insulin Sales Market Share by Region (2018-2034)
Figure 34. Asia Pacific Biosimilars Insulin Revenue Market Share by Region (2018-2034)
Figure 35. China Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 36. Japan Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 37. South Korea Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 38. India Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 39. Australia Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 40. China Taiwan Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 41. Indonesia Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 42. Thailand Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 43. Malaysia Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 44. Latin America Biosimilars Insulin Sales Market Share by Country (2018-2034)
Figure 45. Latin America Biosimilars Insulin Revenue Market Share by Country (2018-2034)
Figure 46. Mexico Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 47. Brazil Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 48. Argentina Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 49. Colombia Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 50. Middle East & Africa Biosimilars Insulin Sales Market Share by Country (2018-2034)
Figure 51. Middle East & Africa Biosimilars Insulin Revenue Market Share by Country (2018-2034)
Figure 52. Turkey Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 53. Saudi Arabia Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 54. UAE Biosimilars Insulin Revenue Growth Rate (2018-2034) & (US$ Million)
Figure 55. Global Sales Market Share of Biosimilars Insulin by Type (2018-2034)
Figure 56. Global Revenue Market Share of Biosimilars Insulin by Type (2018-2034)
Figure 57. Global Biosimilars Insulin Price (USD/Unit) by Type (2018-2034)
Figure 58. Global Sales Market Share of Biosimilars Insulin by Application (2018-2034)
Figure 59. Global Revenue Market Share of Biosimilars Insulin by Application (2018-2034)
Figure 60. Global Biosimilars Insulin Price (USD/Unit) by Application (2018-2034)
Figure 61. Biosimilars Insulin Value Chain
Figure 62. Biosimilars Insulin Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries